321 related articles for article (PubMed ID: 30228937)
1. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.
Wang L; Jia B; Claxton DF; Ehmann WC; Rybka WB; Mineishi S; Naik S; Khawaja MR; Sivik J; Han J; Hohl RJ; Zheng H
Oncoimmunology; 2018; 7(9):e1469594. PubMed ID: 30228937
[TBL] [Abstract][Full Text] [Related]
2. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
Ge MJ; Xu KL; Xu T; Tang YN; Li ZY; Yan ZL; Sun HY; Cheng H; Zhu F; Sang W; Huang YH; Qiu TT; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value.
Pagliuca S; Gurnari C; Zhang K; Kewan T; Bahaj W; Mori M; Nautiyal I; Rubio MT; Ferraro F; Maciejewski JP; Wang L; Visconte V
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499220
[TBL] [Abstract][Full Text] [Related]
4. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia.
Mo J; Deng L; Peng K; Ouyang S; Ding W; Lou L; Lin Z; Zhu J; Li J; Zhang Q; Wang P; Wen Y; Chen X; Yue P; Lu JJ; Zhu K; Zheng Y; Wang Y; Zhang X
J Hematol Oncol; 2023 Feb; 16(1):15. PubMed ID: 36849939
[TBL] [Abstract][Full Text] [Related]
5. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
Kim TK; Han X; Hu Q; Vandsemb EN; Fielder CM; Hong J; Kim KW; Mason EF; Plowman RS; Wang J; Wang Q; Zhang JP; Badri T; Sanmamed MF; Zheng L; Zhang T; Alawa J; Lee SW; Zeidan AM; Halene S; Pillai MM; Chandhok NS; Lu J; Xu ML; Gore SD; Chen L
J Clin Invest; 2024 Feb; 134(3):. PubMed ID: 38060328
[TBL] [Abstract][Full Text] [Related]
6. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
7. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
8. CD26
Zhou H; Jia B; Annageldiyev C; Minagawa K; Zhao C; Mineishi S; Ehmann WC; Naik SG; Cioccio J; Wirk B; Songdej N; Rakszawski KL; Nickolich MS; Shen J; Zheng H
Front Immunol; 2023; 14():1169144. PubMed ID: 37457737
[TBL] [Abstract][Full Text] [Related]
9. Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction.
Mostböck S; Wu HH; Fenn T; Riegler B; Strahlhofer S; Huang Y; Hansen G; Kroe-Barrett R; Tirapu I; Vogt AB
Front Immunol; 2022; 13():862757. PubMed ID: 35967294
[TBL] [Abstract][Full Text] [Related]
10. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
11. Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.
Niu X; Wu M; Li G; Zhou X; Cao W; Zhai W; Wu A; Zhou X; Jin S; Chen G; Li Y; Du J; Wu Y; Qiu L; Zhao W; Gao Y
Acta Pharm Sin B; 2023 Nov; 13(11):4511-4522. PubMed ID: 37969728
[TBL] [Abstract][Full Text] [Related]
12. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
13. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
[TBL] [Abstract][Full Text] [Related]
14. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Böger C; Behrens HM; Krüger S; Röcken C
Oncoimmunology; 2017; 6(4):e1293215. PubMed ID: 28507801
[TBL] [Abstract][Full Text] [Related]
15. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.
Zhu L; Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Palmisiano ND; Wang M; Jia B; Bayerl M; Schell TD; Hohl RJ; Zeng H; Zheng H
J Hematol Oncol; 2017 Jun; 10(1):124. PubMed ID: 28629373
[TBL] [Abstract][Full Text] [Related]
16. Expression of the immune checkpoint VISTA in breast cancer.
Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
[TBL] [Abstract][Full Text] [Related]
17. Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with
Tan J; Chen S; Lu Y; Yao D; Xu L; Zhang Y; Yang L; Chen J; Lai J; Yu Z; Zhu K; Li Y
Chin J Cancer Res; 2017 Oct; 29(5):463-470. PubMed ID: 29142466
[TBL] [Abstract][Full Text] [Related]
18. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
Front Immunol; 2019; 10():1638. PubMed ID: 31379838
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
Choi JW; Kim YJ; Yun KA; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
Sci Rep; 2020 Sep; 10(1):14372. PubMed ID: 32873829
[TBL] [Abstract][Full Text] [Related]
20. Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling.
Tohumeken S; Baur R; Böttcher M; Stoll A; Loschinski R; Panagiotidis K; Braun M; Saul D; Völkl S; Baur AS; Bruns H; Mackensen A; Jitschin R; Mougiakakos D
Cancer Res; 2020 Sep; 80(17):3663-3676. PubMed ID: 32605996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
